Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

作者：Silvio Danese, Jessica R. Allegretti, Stefan Schreiber, Laurent Peyrin‐Biroulet, Vipul Jairath, Geert D’Haens, Jarosław Kierkuś, Rupert Wing Loong Leong, Andres J. Yarur, Michael St. Vincent, Anindita Banerjee, Deepa E. Chandra, Elena Peeva, Srividya Neelakantan, Kenneth E. Hung, Jacqueline McBride, Daniela Bojic, Karen L. Lasch, Courtney Schiffman, Brian G. Feagan · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2025 · DOI：10.1016/s2468-1253(25)00129-3 · 被引用次数：25 · 研究领域：Inflammatory Bowel Disease、Rheumatoid Arthritis Research and Therapies、Immune Response and Inflammation